Drug intelligence / Profile preview

Respirogen Micro-Oxygen

Development stage: Unknown
Lead developer: Respirogen
Modality: Nanoparticles → Drug Delivery Systems
Administration: Rectal

Overview

Respirogen Micro-Oxygen (RMO) is an oxygen delivery technology consisting of oxygen-filled microbubbles designed to provide systemic oxygenation independent of pulmonary function. Developed by Respirogen, the technology utilizes lipid-stabilized microbubbles that can be administered enterally (rectally) to bypass the lungs and deliver oxygen directly to the bloodstream via the gastrointestinal tract. It is primarily being investigated for the treatment of respiratory distress, pulmonary dysfunction, and hypoxemia, particularly in clinical settings where traditional ventilation is insufficient or in low-oxygen environments.

Brand names: Respirogen Micro-Oxygen
Other names: Respirogen Oxygen Microbubble TechnologyOxygen Microbubbles

Beyond the preview

Go deeper on Respirogen Micro-Oxygen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respirogen Micro-Oxygen.

Explore the full profile